Neurocrine Grows in Endocrinology, Rare Disease with $2.9B Soleno Buyout

VykatPositive

AI Analysis

Summary

Neurocrine Biosciences announced a $2.9 billion acquisition of Soleno Therapeutics, which generated $190.4 million in net revenue from Vykat sales in 2025. Vykat is positioned as a first-line therapy for Prader-Willi Syndrome with patent protection expected through the mid-2040s.

Financial Highlights

Revenue

$190.4 million (Vykat 2025)

Outcome Details

$2.9 billion acquisition deal

Importance:8/10

Sentiment:

0.70

M&Aacquisitionendocrinologyrare diseasePrader-Willi Syndromerevenue growth

Related Companies

$NBIX $SLNO

Read the original article

Published by GEN - Genetic Engineering & Biotech News on April 7, 2026 8:01 PM

Read Original